Burning Rock Biotech Limited American Depositary Receipt (BNR)

Overview

Burning Rock Biotech Limited is a pioneering company focused on the development and commercialization of cancer therapy selection tests within the People's Republic of China. Since its incorporation in 2014, the company has established a prominent presence in the oncology diagnostics market through its operations across three primary segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. With its commitment to innovation and quality, Burning Rock Biotech aims to enhance cancer treatment efficacy by providing advanced next-generation sequencing (NGS)-based tests. These tests span a wide range of cancers, aiming to revolutionize the approach to cancer therapy selection and prognosis prediction. Headquartered in Guangzhou, China, the company also engages in significant partnerships and collaborations with leading pharmaceutical entities and research organizations, thereby furthering its impact on the oncological landscape.

Products and Services

• OncoCompass IO: A groundbreaking test designed for liquid biopsy samples, facilitating cutting-edge cancer therapy selection. This test enables the identification of optimal therapeutic pathways for patients, leveraging the potential of liquid biopsies in oncology.
• OncoScreen IO: Tailored for tissue samples, OncoScreen IO serves as a pan-cancer test that encompasses a broad spectrum of cancer types. Its next-generation sequencing capabilities ensure comprehensive analysis and insights for therapy selection.
• OncoCompass Target: Specifically focused on non-small cell lung cancer (NSCLC), this ctDNA liquid biopsy-based test is at the forefront of targeted therapy selection, offering a non-invasive yet highly precise diagnostic option.
• ColonCore: A specialized test aimed at gastrointestinal cancers, ColonCore assesses microsatellite loci related to MSI status while also detecting mutations in genes associated with these cancer types. It is a pivotal tool for both diagnosis and treatment guidance.
• brPROPHET: This innovative test provides a dual approach to managing cancer treatment, with pre-operative ctDNA detection and post-operative minimal residual disease (MRD) calling for patients at risk of relapse. It represents a significant advancement in the ongoing surveillance and management of cancer.
• OncoMaster: An automatic NGS data analysis and report interpretation machine specially designed for the in-hospital model. OncoMaster streamlines the diagnostic process, enhancing the efficiency and accuracy of cancer treatment selection in medical institutions.

In addition to its flagship products, Burning Rock Biotech engages in strategic partnerships and licensing agreements to expand its portfolio and access innovative technologies. Notable collaborations include agreements with Myriad Genetics, Inc. for the myChoice tumor testing, Oncocyte Corporation for the DetermaRx test, and numerous clinical trials and research studies with industry leaders such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA. These partnerships facilitate the entrance of cutting-edge oncology diagnostic tools into the Chinese market, further underpining Burning Rock Biotech’s role in transforming the landscape of cancer treatment.